Genetic Markers Associated with Endometriosis and Use Thereof
AssigneeJuneau Biosciences, LLC
InventorsKenneth Ward, Hans Albertsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis.
Claims50
A method for determining whether a human subject has altered risk of developing endometriosis, comprising:
- detecting in the genetic material of said subject the presence or absence of one or more protective or high-risk polymorphism selected from the group consisting of the polymorphisms of Table 1 or Table 2, or a polymorphism that is in linkage disequilibrium with a polymorphism of Table 1 or Table 2,
- wherein the polymorphism is correlated with altered risk of endometriosis.
A method for determining whether a human subject has altered risk of developing endometriosis, comprising:
- detecting in the genetic material of said subject the presence or absence of one or more protective or high-risk polymorphism selected from the group consisting of the polymorphisms of Table 1 or Table 2, or a polymorphism that is in linkage disequilibrium with a polymorphism of Table 1 or Table 2, wherein the polymorphism is correlated with altered risk of developing endometriosis, and
- evaluating the risk associated with one or more non-genetic clinical factors selected from the group consisting of age at menarche, BMI and other factors associated with endometriosis.
An amplified polynucleotide containing the nucleotide sequence of a polymorphism selected from the polymorphisms of Table 1 or Table 2, or a polymorphism that is in linkage disequilibrium with a polymorphism of Table 1 or Table 2, or a complement thereof, wherein the amplified polynucleotide is greater than about 16 nucleotides in length.
An isolated polynucleotide that specifically hybridizes to a polynucleotide molecule containing the nucleotide sequence of a polymorphism selected from any one of the polymorphisms of Table 1 or Table 2, or a polymorphism that is in linkage disequilibrium with a polymorphism of Table 1 or Table 2, or a complement thereof.
A method of detecting in a nucleic acid molecule a polymorphism that is correlated altered risk of developing endometriosis, comprising:
- contacting a test sample with a polynucleotide sequence that specifically hybridizes under stringent hybridization conditions to a polynucleotide sequence having one or more protective or high-risk polymorphism selected from the group consisting of the polymorphisms of Table 1 or Table 2, or a polymorphism that is in linkage disequilibrium with a polymorphism of Table 1 or Table 2, or a complement thereof, wherein the polymorphism is correlated with altered risk of developing endometriosis, and
- detecting the formation of a hybridized duplex.
An apparatus for detecting endometriosis mutations comprising:
- a DNA chip array comprising a plurality of polynucleotides attached to the array, wherein each polynucleotide contains a polymorphism selected from the group consisting of the polymorphisms set forth in Table 1 or Table 2, or a polymorphism that is in linkage disequilibrium with a polymorphism of Table 1 or Table 2, or a complement thereof,
- and a device for detecting the SNPs.
A method for identifying a polymorphism that is correlated with altered risk of developing endometriosis, wherein the method comprises the step of identifying a polymorphism that is in linkage disequilibrium with a polymorphism set forth in Tables 1-196.
A method of screening human subjects, said method comprising the following steps:
- obtaining a genetic material sample of a human subject,
- inspecting said genetic material,
- detecting in said genetic material the presence or absence of at least one human gene associated genetic marker that is correlated with at least one endometriosis related condition of the following group of endometriosis related conditions comprising an endometriosis existence condition, an endometriosis nonexistence condition, a risk of developing endometriosis condition, and a risk of endometriosis progression condition, wherein said human gene of said human gene association of said genetic marker is selected from any human gene except for a human gene of the following group of human genes comprising ACE, ADAR, AEBP1, AhRR, AHSG, APOE, AR, BRAF, C3, CCL5, CDH1, CLDN4, COL1A2, COL3A1, COMT, CSRP1, CSTB, CTSD, CYP1A1, CYP1B1, CYP17A1, CYP19A1, CYP27B1, DUSP1, EF1alpha, EGFR, EGR1, ERalpha, ERbeta, ESR1, ESR2, FAS, FASLG, FLT-1, FSHR, FTL, GALT, GSN, GSTM1, GSTP1, GSTT1, GSTT1, HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HRF, HSD17B1, HSD17B1, IB-1, ICAM-1, IFNG, IGFBP3, IGL, IL-1R, IL-1RA, IL-2R, IL-6, IL-10, KRAS, LTA, MCAM, MMP1, MMP3, MMP7, NACA, NAT2, NOS3, NR3C1, NRIP1, P4HB, PAEP, PAI1, PCOLCE, PGR, PLAT (tPA), PLAU (uPA), PODXL, PPARgamma2, PSAP, PTEN, RACK1, RAD21, RANTES, RPS6, SERPINA1, SERPINE1, SFRP4, StAR, STAT6, STMY3, TAFI, TCN2, TGFbeta1, TNFalpha, TNFR2, TNFRSF1B, TSG, VEGF, VEGF, VEGFR, and
- responding to said detection of said genetic marker.
Dependencies are inferred from the claim text.